RxDoctor Payments Data

Rekha Pinto, MD

Cardiovascular Disease · Butler, PANPI 1215122775

Payments from drug & device makers

$32,949in general payments, 2019–2025

Across 552 payments — averaging $59.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Heartflow, Inc.$25K
  • Johnson & Johnson$994
  • E.r. Squibb & Sons, L.L.C.$811
  • AstraZeneca$699
  • Novartis$690
  • Pfizer$630
  • plus $4K from 36 others

What the payments were for

  • Travel & lodging$7317%
  • Food & beverage$8,98091%
  • Education$1872%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,949 in reported general payments places this provider in the 85th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$73,651
Medicare patients
503
Services billed
1,047

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban458$427,837
XareltoRivaroxaban249$234,988
Repatha SureclickEvolocumab281$202,587
JardianceEmpagliflozin127$128,122
EntrestoSacubitril/Valsartan80$106,796
MultaqDronedarone Hcl62$92,989
FarxigaDapagliflozin Propanediol108$89,506
BrilintaTicagrelor55$56,954
OzempicSemaglutide20$21,800
WegovySemaglutide13$17,283
Ranolazine ErRanolazine107$14,556
VascepaIcosapent Ethyl13$11,918
Praluent PenAlirocumab20$10,064
Rosuvastatin Calcium647$9,724
Metoprolol Succinate487$7,622

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$630$427,837458 claims
Johnson & JohnsonXarelto$994$234,988249 claims
AstraZenecaFarxiga, Brilinta$699$146,460163 claims
Boehringer IngelheimJardiance$366$128,122127 claims
NovartisEntresto$690$106,79680 claims
Sanofi-aventis U.S. LLCMultaq$322$92,98962 claims
Novo NordiskOzempic, Wegovy$160$39,08333 claims
AmgenCorlanor$459$89846 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Butler

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →